[18F]-FDG PET在肛管癌中的应用:系统评价与Meta分析
该系统评价与Meta分析依据PRISMA-DTA指南,纳入截至2022年12月发表的原始研究,评估[18F]-FDG PET对肛管癌原发肿瘤、T分期、淋巴结及远处转移的诊断价值与预后价值。28项研究进入Meta分析,15项研究数据进行描述性报告;PET区分T3/T4与其他T分期的汇总敏感度91%、特异度96%,检测转移性疾病敏感度100%、特异度95%,疗效评估敏感度96%、特异度86%;治疗前总代谢肿瘤体积较高预示生存较差,达到完全代谢缓解者2年PFS为94%而其他患者为51%(P<0.001)。结论认为PET可能有助于肛管癌治疗计划制定并提供有价值的预后信息。
要点
- PET区分T3/T4与其他T分期的汇总敏感度91%(95%CI 72%-97%)、特异度96%(95%CI 88%-98%)。
- PET检测转移性疾病(区域和/或远处)的敏感度100%(95%CI 82%-100%)、特异度95%(95%CI 90%-98%)。
- 达到完全代谢缓解者2年PFS 94%(95%CI 91%-97%),其他患者51%(95%CI 42%-59%),P<0.001。
核心结论
- PET可能有助于肛管癌治疗计划制定,并提供有价值的预后信息。
研究设计与样本
- 本系统评价与Meta分析依据PRISMA-DTA指南设计,检索截至2022年12月发表的原始研究,纳入标准为评估PET对组织病理学证实的肛管癌区域和/或远处病灶检测、与有效参考标准比较并提供可计算Meta分析估计的粗数据。
- 28项研究纳入Meta分析计算,15项研究的数据进行描述性报告;采用分层法进行汇总Meta分析计算,双变量模型获取汇总估计,使用STATA 16进行分析。
主要发现
- PET区分T3/T4与其他T分期的汇总敏感度91%(95%CI 72%-97%)、特异度96%(95%CI 88%-98%)。
- PET检测转移性疾病(区域和/或远处)的敏感度100%(95%CI 82%-100%)、特异度95%(95%CI 90%-98%)。
- PET评估治疗反应的敏感度96%(95%CI 78%-99%)、特异度86%(95%CI 75%-93%)。
- 治疗前总代谢肿瘤体积较高预示生存较差。
- 达到完全代谢缓解者2年PFS为94%(95%CI 91%-97%),其他患者为51%(95%CI 42%-59%),P<0.001。
关键数值与推荐
- 区分T3/T4与其他T分期:汇总敏感度91%(95%CI 72%-97%)、特异度96%(95%CI 88%-98%)。
- 检测转移性疾病(区域和/或远处):敏感度100%(95%CI 82%-100%)、特异度95%(95%CI 90%-98%)。
- 评估治疗反应:敏感度96%(95%CI 78%-99%)、特异度86%(95%CI 75%-93%)。
- 完全代谢缓解者2年PFS 94%(95%CI 91%-97%)vs 其他患者51%(95%CI 42%-59%),P<0.001。
临床怎么用
- PET可能有助于肛管癌治疗计划制定,并可提供有价值的预后信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide comprehensive data on the diagnostic and prognostic value of [18F]-FDG PET (PET) in anal canal cancer patients. METHODS: This study was designed following the PRISMA-DTA guidelines. For the meta-analysis, published original articles (until December 2022) that met the following criteria were included: Evaluated PET for locoregional and/or distant disease detection in patients with histopathology-proven anal canal cancer; Compared PET with a valid reference standard; Provided crude data to calculate meta-analytic estimates. Diagnostic measurements from subgroups were calculated in evaluating primary tumour detection, T stage, lymph node and distant metastases. Articles providing prognostic information on PET were also reported as a systematic review. For pooled meta-analytic calculations, the hierarchical method was used. The bivariate model was conducted to find the summary estimates. Analyses were performed using STATA 16. RESULTS: After the screening, 28 studies were eligible to enter the meta-analytic calculations, and data from 15 were reported descriptively. For distinguishing T3/T4 from other T-stages, PET had pooled sensitivity and specificity of 91%(95%CI:72%-97%) and 96%(95%CI:88%-98%), respectively. The sensitivity and specificity for detecting metastatic (regional and/or distant) disease were 100% (95%CI:82%-100%) and 95% (95%CI:90%-98%), respectively. For therapy response assessment, the sensitivity and specificity of PET were 96%(95%CI:78%-99%) and 86%(95%CI:75%-93%), respectively. Higher pre-treatment total metabolic tumour volume was predictive of poorer survival. Conversely, for those achieving complete metabolic response, the 2-year PFS was 94%(95%CI:91%-97%) versus 51%(95%CI:42%-59%) for others (p-value < 0.001). CONCLUSION: PET may be a useful tool for anal canal cancer therapy planning and provides valuable prognostic information.
引用
- Mirshahvalad SA, Mesci A, Murad V, et al. [18F]-FDG PET in anal canal cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2023. PMID: 37592085. doi:10.1007/s00259-023-06393-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。